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LKB1 loss links serine metabolism to 
DNA methylation and tumorigenesis
Filippos Kottakis1,2,3, Brandon N. Nicolay1,3, Ahlima Roumane1,2,3, Rahul Karnik4,5,6, Hongcang Gu4,5,6, Julia M. Nagle1,2,3, 
Myriam Boukhali1,3, Michele C. Hayward7, Yvonne Y. Li8,9, Ting Chen8,9,10, Marc Liesa11,12, Peter S. Hammerman8,9,13, 
Kwok Kin Wong8,9,10, D. Neil Hayes7, Orian S. Shirihai11,12, Nicholas J. Dyson1,3, Wilhelm Haas1,3, Alexander Meissner4,5,6 & 
Nabeel Bardeesy1,2,3
Substrates and inhibitors of chromatin-modifying enzymes are gen-
erated in intermediary metabolism, so changes in nutrient availability 
and utilization can influence epigenetic regulation1,2. Importantly, 
recent studies have indicated that the interplay between metabolism 
and epigenetics can serve as a programmed switch in cell states. For 
example, mouse embryonic stem cell differentiation is promoted by 
succinate-mediated inhibition of histone demethylases (HDMs) and 
TET DNA demethylases3, or by decreased S-adenosyl-methionine 
(SAM) levels leading to loss of histone H3K4 methylation4. Moreover, 
aberrant metabolic activity can produce pathological effects by altering 
chromatin regulation. Most notably, mutations in the genes encoding 
the isocitrate dehydrogenase (IDH)1 and IDH2 enzymes lead to the 
generation of 2-hydroxyglutarate, which inhibits HDMs and TETs and 
thereby alters DNA and histone methylation—changes that have been 
implicated in overriding cell differentiation and promoting tumorigenesis5. 
Whether this paradigm extends more generally to other oncogenic 
mutations remains unclear, and this question has implications for 
understanding cancer pathogenesis and developing improved treat-
ments. Here, we demonstrate that dynamic exchange between metabo-
lism and chromatin regulation contributes to pancreatic tumorigenesis 
driven by mutation of the LKB1 serine–threonine kinase.
LKB1 is mutationally inactivated in a range of sporadic cancers, 
including pancreatic carcinomas6–8. Additionally, germline mutations 
in LKB1 cause Peutz-Jeghers syndrome, which comprises gastrointesti-
nal polyps and a high incidence of gastrointestinal tract carcinomas (for 
example, an approximately 100-fold increase in pancreatic cancer)9,10. 
Cancers with LKB1 mutations tend to exhibit aggressive clinical fea-
tures and different therapeutic sensitivity from cancers without these 
mutations11–14. LKB1 directly activates a family of 14 kinases related 
to AMP-activated protein kinase (AMPK), many of which are coupled 
to nutrient sensing and broadly reprogram cell metabolism15. Thus, 
metabolic rewiring is thought to be a driver of tumorigenesis after LKB1 
loss. We now identify an LKB1-regulated program that links metabolic 
alterations to control of the epigenome and is involved in malignant 
growth. Our results provide evidence that coupled metabolic and epige-
netic states have a more general role in cancer pathogenesis and suggest 
therapeutic strategies that could target these intersecting processes.
Synergy between LKB1 and KRAS mutations
LKB1 inactivation frequently coincides with mutations in the RAS–RAF 
pathway in human cancers and these genetic alterations cooperate 
to drive tumorigenesis in genetically engineered mouse models 
(GEMMs)6,11,14,16. We examined the interactions between oncogenic 
KRASG12D and deletion of LKB1 in adult pancreatic ducts using a 
tamoxifen-inducible GEMM (Extended Data Fig. 1a). The combined 
alterations resulted in pancreatic cancers by 20–25 weeks, whereas the 
individual mutations had no pathological effects at this age (Fig. 1a and 
Extended Data Fig. 1b). To investigate the mechanisms of tumorigenesis, 
we isolated primary pancreatic ductal epithelial cells from mice with 
conditional KRASG12D and LKB1 alleles (n = 2 lines per genotype) and 
transduced them with adenoviruses expressing Cre and/or Flp recom-
binase to generate KRASG12D/+, LKB1−/− and KRASG12D/+;LKB1−/− 
cells (K, L and KL cells, respectively) as well as wild-type parental lines 
(Extended Data Fig. 1c). Only KL cells were tumorigenic following 
injection into severe combined immunodeficient (SCID) mice or 
growth in soft agar, and tumorigenicity was blocked by restoration of 
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wild-type LKB1 (Fig. 1b and Extended Data Fig. 1d–g). In vitro, KL 
cells showed greater proliferation than K cells, and both showed greater 
proliferation than wild-type or L cells (Extended Data Fig. 1h–j). Thus, 
primary ductal cells provide a tractable in vitro system to study mecha-
nisms of epithelial cell transformation arising from LKB1 inactivation.
Focusing on the metabolic alterations provoked by loss of LKB1, we 
found that KL cells exhibited an approximately 30% increase in glucose 
uptake compared to K cells, and showed marked elevations in levels of 
the GLUT1 transporter and ATP (Fig. 1c and Extended Data Fig. 1k, l). 
Lactate levels were elevated in KL cells, whereas oxygen consumption 
and citrate levels were reduced (Fig. 1d, e and Extended Data Fig. 1m). 
Moreover, KL cells showed heightened sensitivity to acute glucose 
deprivation and to inhibition of glycolysis using the glucose analogue 
2-deoxyglucose, the pyruvate dehydrogenase kinase inhibitor dichlo-
roacetate, or the lactate dehydrogenase inhibitor galloflavin (Extended 
Data Fig. 1n–q). Importantly, neither KRASG12D nor LKB1 inactiva-
tion alone promoted significant alterations in glucose metabolism 
(Extended Data Fig. 1r–t). Thus, these genetic lesions acted synergis-
tically to potentiate glycolysis while rendering cells highly dependent 
on glucose availability.
These data suggested that an increased supply of glycolytic inter-
mediates was available for anabolic processes to support the growth 
of KL cells (Fig. 1f). Notably, gene set enrichment analysis (GSEA) of 
RNA-sequencing (RNA-seq) and quantitative proteomics17 data indi-
cated that KL cells are enriched for glycolytic enzymes and for net-
works that connect glycolytic intermediates to one-carbon metabolism, 
with serine–glycine–threonine and folate metabolism scoring highly 
among the induced pathways (Supplementary Data Table 1). There 
was particularly striking enrichment of a 64-gene signature defining 
the entire serine–glycine–one carbon (SGOC) network18, indicating 
strong coordinate activation of these pathways (Fig. 1g and Extended 
Data Fig. 2a). Accordingly, the use of uniformly carbon-13-labelled 
glucose (U[13C]glucose) demonstrated that KL cells show augmented 
production of glucose-derived pyruvate and lactate and an even more 
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Figure 1 | LKB1 inactivation synergizes with KRASG12D to potentiate 
glycolysis, serine metabolism, and tumorigenesis. a, Representative 
pancreas histology of the indicated genotypes of mice at 20–25 weeks 
(n = 4 per genotype). b, Subcutaneous tumour growth of KL cells 
expressing empty vector (KL) or LKB1 (rescue) (n = 8 per group).  
c, d, Ductal cells tested for glucose uptake (c; n = 6, independent 
replicates), and lactate secretion (d; n = 3). e, Oxygen consumption rates 
in K and KL cells under nutrient-replete conditions (n = 21). f, Fates of 
glycolytic intermediates. g, GSEA showing enrichment of serine–glycine–
one-carbon network18 (K cells, n = 3; KL cells, n = 4). NES, normalized 
enrichment score. h, i, Isotopomer abundance of U[13C]glucose-derived 
M+ 3 pyruvate (h) or serine (i; n = 3, biological replicates). Data pooled 
from three (e) or representative of two (d) experiments. Error bars,  
s.e.m. (b), s.d. (c, d, g, h). * P < 0.05, * * P < 0.01, * * * P < 0.001.
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Figure 2 | Activation of de novo serine biosynthesis supports growth of 
LKB1-deficient cells. a, Serine biosynthesis pathway. Red, upregulated 
in KL cells. b, Serine pathway gene expression (n = 8 per genotype). 
c, Isotopomer abundance of [15N]glutamine-derived M+ 1 serine and 
glycine (n = 3, biological replicates). d, e, Three-day growth of ductal 
cells cultured with or without 0.4 mM serine (d; n = 20) or transduced 
with the indicated shRNAs (e; n = 6). f, Six-day proliferation of KL cells 
transduced with the indicated shRNAs and expression constructs (n = 3). 
g, Subcutaneous growth of tumours from KL cells transduced with the 
indicated shRNAs (n = 12 tumours per group). h, Proportion of CK19+ 
tumours cells that are PCNA+ (shControl n = 4, shPSAT1-1 n = 4, 
shPSAT1-2 n = 3, representative tumours). Data pooled from four (b) or 
representative of two (e, f) or four (d) experiments. Error bars: s.d. (b–f), 
s.e.m. (g, h). * P < 0.05, * * P < 0.01, * * * P < 0.001.
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pronounced increase in serine and glycine biosynthesis rates without 
changes in total levels of these amino acids (Fig. 1h, i and Extended 
Data Fig. 2b–d).
Serine pathway dependence of KL cells
Multiple serine pathway enzymes (PSAT1, PSPH, SHMT1 and 
SHMT2) were upregulated in KL cells, whereas restoration of LKB1 
expression reversed these changes, broadly suppressed the entire SGOC 
network, and reduced serine biosynthesis (Fig. 2a, b and Extended 
Data Fig. 2e–g). PSAT1 catalyses the transamination of 3-phospho- 
hydroxy-pyruvate (3PHP) to 3-phosphoserine (3PS), with glutamate as 
the nitrogen donor and α -ketoglutarate (α -KG) as a secondary prod-
uct (Fig. 2a). Consistent with elevated PSAT1 activity, [15N]glutamine 
labelling revealed a marked increase in nitrogen incorporation into 
serine and glycine in KL cells (Fig. 2c). Thus, LKB1 restricts serine 
metabolism.
Consistent with this finding, KL cells were unaffected by culturing 
in serine-free medium, whereas K cells showed a roughly 40% decrease 
in proliferation, as did KL cells in which LKB1 was expressed (Fig. 2d 
and Extended Data Fig. 3a). On the other hand, KL cells were specifi-
cally sensitive to PSAT1 knockdown, exhibiting reduced proliferation 
in normal medium, restored dependency on exogenous serine, and 
impaired colony formation in soft agar (Fig. 2e and Extended Data 
Fig. 3b–d). Introduction of short hairpin (sh)RNA-resistant human 
PSAT1 cDNA rescued these phenotypes (Fig. 2f and Extended Data 
Fig. 3e). Moreover, PSAT1 knockdown strongly inhibited subcutaneous 
tumour growth by KL cells (Fig. 2g, h and Extended Data Fig. 3f, g). 
Notably, PSAT1 knockdown had no effect on the proliferation or tum-
origenicity of cell lines from pancreatic cancer GEMMs with wild-
type LKB1 (KRASG12D-p53 null, KPC and KRASG12D-CDKN2A null, 
KIC)19, supporting the idea that these effects result from LKB1 loss 
rather than being secondary to high proliferation rates (Extended Data 
Fig. 3b, h–k). Thus, increased serine biosynthesis pathway activity is 
required to drive oncogenic transformation in KL cells.
Serine biosynthesis fuels DNA methylation
The serine biosynthesis pathway can fuel a range of anabolic pro-
cesses, including generation of N5,N10-methylene-tetrahydrofolate 
(THF), which supports NADPH production, redox homeostasis, and 
nucleotide biosynthesis20. PSAT1 knockdown failed to increase levels 
of reactive oxygen species (ROS) in KL cells and, correspondingly, 
proliferation was not restored by the ROS scavenger N-acetylcysteine 
(NAC) or by nucleoside supplementation (Extended Data Fig. 4a–d). 
Similar results were obtained after treatment with aminooxyacetate 
(AOA), an inhibitor of PSAT1 and other aminotransferases (Extended 
Data Fig. 4e, f). Thus, the requirement of KL cells for PSAT1 appears 
to be independent of its roles in redox homeostasis or maintenance of 
nucleoside pools.
Serine metabolism can also fuel the methionine salvage pathway 
(Fig. 3a), which is the main mechanism of production for the methyl 
donor S-adenosyl methionine (SAM)21,22. Notably, multiple enzymes 
that channel serine metabolism intermediates into the methionine 
salvage pathway and that contribute to SAM biosynthesis were upreg-
ulated in KL cells (Extended Fig. 4g). Accordingly, PSAT1 knockdown 
reduced SAM levels in KL cells but not in K cells (Fig. 3b). Furthermore, 
SAM supplementation mitigated the proliferation defects caused by 
PSAT1 ablation in KL cells (Fig. 3c). Conversely, suppression of SAM 
biosynthesis by inhibition of S-adenosyl-homocysteine-hydrolase 
(SAH) with 3-deazaadenosine (3DZA), or of methionine-adenosyl- 
transferase (MAT) with cycloleucine, slowed the growth of KL cells, 
whereas K cells remained unaffected (Fig. 3d and Extended Data 
Fig. 4h). Thus, activation of de novo serine biosynthesis contributes to 
SAM production to support growth of LKB1-deficient cells, possibly 
by providing active methyl groups in the form of N5-methyl-THF, or by 
promoting ATP generation (for example, via PSAT1-dependent TCA 
cycle anaplerosis)22,23.
SAM is the substrate for methylation of lipids, DNA, RNA, 
 metabolites and proteins. Examination of our RNA-seq and  proteomics 
data sets for the expression of the 183 annotated SAM-dependent 
 methyltransferase enzymes revealed significant upregulation of the 
DNA methyltransferases DNMT1 and DNMT3A in KL cells, whereas 
few of the other enzymes showed any changes (Fig. 3e, Extended Data 
Fig. 5a and Supplementary Data Table 2). Quantitative PCR and immu-
noblot analyses verified the regulation of expression of these enzymes 
by LKB1 (Extended Data Fig. 5b, c). Importantly, inhibition of DNA 
methylation using 5-aza-2-deoxycytidine (decitabine) or the non- 
nucleoside DNMT inhibitor RG108 promoted SAM accumulation in KL 
cells but not in K cells (Extended Data Fig. 5d), suggesting that DNMTs 
are major SAM-utilizing enzymes in the context of LKB1 deficiency.
Accordingly, immunofluorescence and DNA dot blot analysis demon-
strated that KL cells had a significant increase in 5-methylcytosine 
(5mC) as compared to K cells, an effect that was reversed by LKB1 
rescue (Extended Data Fig. 5e–g). By contrast, there were no consistent 
changes in global levels of a series of histone methylation marks, in 
5-hydroxy-methylcytosine, or in N6-methyladenosine (Extended Data 
Fig. 5h–i and data not shown). Notably, PSAT1 knockdown suppressed 
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Figure 3 | Activation of the SGOC network promotes DNA methylation 
in LKB1-deficient cells. a, SGOC network. b, SAM levels in ductal cells 
transduced with the indicated shRNAs (n = 4). c, Three-day growth of 
KL cells with or without SAM supplementation or PSAT1 knockdown 
(n = 16). d, Proliferation of ductal cells treated with 3-deazaadenosine  
(3-DZA) (n = 12). e, Heatmap of differentially regulated SAM-using 
enzymes (proteomics). f, 5mC in ductal cells (77–177 cells). Data pooled 
from two (c, d, f) or representative of two (b) experiments. Error bars:  
s.d. (b–d), s.e.m. (f). * P < 0.05, * * P < 0.01, * * * P < 0.001.
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DNA methylation in KL cells, and this effect was reversed by shRNA- 
resistant PSAT1 cDNA, while K and KPC controls were unaffected. 
(Fig. 3f and Extended Data Fig. 6a–c). Comparison of all four genotypes 
using our set of isogenic ductal cells confirmed that serine pathway 
activity and DNA methylation were specifically potentiated upon dual 
KRASG12D expression and LKB1 loss (Extended Data Fig. 6d–g).
The expression of a kinase-dead (KD) LKB1 mutant confirmed that 
the activation of key transcriptional and metabolic circuits in KL cells 
was due to loss of LKB1 kinase activity (Extended Data Fig. 7a–e). 
Accordingly, KL cells showed reduced activity of AMPK, an important 
target of the LKB1 kinase, and consequent activation of mechanistic 
target of rapamycin complex I (mTORC1) (Extended Data Fig. 7f, w). 
Moreover, in K cells, AMPK suppression using the small molecule 
inhibitor dorsomorphin (compound C) or shRNAs targeting AMPKα 1 
or AMPKα 2 increased each of the metabolic and gene expression 
parameters and upregulated global DNA methylation levels,  mimicking 
the effects of LKB1 loss (Extended Data Fig. 7g–q). Additionally, 
AMPK silencing blocked the effects of LKB1 re-expression on the 
growth and metabolic properties of KL cells (Extended Data Fig. 7r–u). 
Finally, KL cells were hypersensitive to mTOR inhibition using Torin 1, 
which suppressed the metabolic and transcriptional changes seen in 
these cells (Extended Data Fig. 7v–z). Thus, deregulation of AMPK–
mTORC1 signalling contributes to the altered metabolic and epigenetic 
network in KL cells.
LKB1 loss silences retrotransposons
DNA methylation can contribute to transcriptional regulation and 
maintenance of genomic stability24. We mapped methylation changes 
by conducting whole-genome bisulphite sequencing (WGBS) of K 
and KL cells (two independently derived lines per genotype). The data 
demonstrated a marked increase in mean CpG methylation in KL 
cells (Fig. 4a and Extended Data Fig. 8a). Comparison of methylation 
levels at non-repetitive 100-bp tiles revealed 3,395 hypermethylated 
and 1,270 hypomethylated regions in KL cells (FDR < 0.05, methyl-
ation difference > 0.1; Fig. 4b and Extended Data Fig. 8b). However, 
the genes associated with differentially methylated regions had only 
modest overlap with those showing differential expression, suggesting 
that methylation of these elements may not prominently affect tran-
scriptional regulation (Extended Data Fig. 8c). Thus, we focused on 
the repetitive portion of the genome. Notably, methylation in KL cells 
was particularly enriched at retrotransposon repeats (long terminal 
repeats (LTRs), long interspersed nuclear elements (LINEs) and short 
interspersed nuclear elements (SINEs)) compared to non-repeat ele-
ments (promoters, CpG islands and shores) (Fig. 4c, d and Extended 
Data Fig. 8d–k). These elements comprise a large proportion of the 
genome, have promoters that can be actively transcribed when unmeth-
ylated, and can influence regulation of host genes25. Consistent with 
a functional role for the observed retrotransposon methylation, KL 
cells had a > 50% reduction in LINE-1 expression compared to K cells 
(Fig. 4e). Moreover, restoration of LKB1 suppressed LINE-1 methyla-
tion, as determined by 5mC–DNA immunoprecipitation–PCR analysis 
(meDIP–qPCR), and led to an approximately twofold upregulation of 
LINE-1 transcript expression (Fig. 4f, g). Importantly, PSAT1 knock-
down also reduced LINE-1 methylation and induced its expression 
in KL cells (Fig. 4h, i), indicating that increased serine metabolism 
supports retrotransposon methylation and transcriptional silencing 
downstream of LKB1 loss.
Because retrotransposons can function as important modulators 
of host gene expression25, we explored the correlation between dif-
ferentially expressed genes in K versus KL cells and the presence of 
linked retrotransposons. Retrotransposon elements were significantly 
enriched (χ2 test, P < 0.0001) in the gene bodies of differentially 
expressed genes as compared to the distribution of these elements 
across all genes (Extended Data Fig. 8l, m). By contrast, minimal 
enrichment was observed when promoter regions were considered. 
Such specificity is notable in light of evidence that intragenic methyl-
ation (including repeat methylation) can modify the activity of linked 
promoters and affect RNA processing25,26. Thus, the LKB1–SGOC 
pathway alters the epigenetic landscape and dynamically regulates 
retrotransposon methylation and transcriptional activity, changes that 
appear to be associated with differences in host gene transcription.
KL cells are sensitive to DNMT inhibition
Consistent with the functional relevance of increased DNA meth-
ylation, KL cells were sensitive to shRNA-mediated knockdown of 
DNMT1 or DNMT3A, whereas K or KPC cells remained largely unaf-
fected (Extended Data Fig. 9a–c). Similar specific sensitivity of KL 
cells was observed in vivo using doxcycline (dox)-inducible shRNAs 
to acutely deplete DNMT1 or DNMT3 (or shGFP control) once subcu-
taneous tumours reached 50 mm3 in size (Fig. 5a–c and Extended Data 
Fig. 9d–f). These data indicate that inhibition of DNA methylation is a 
potential vulnerability of KL cells. Indeed, KL cells were hypersensitive 
Figure 4 | The LKB1–PSAT1 pathway controls methylation and 
expression of retrotransposons. a, Distribution of methylation levels 
in ductal cells. Median values are indicated. b, Heatmap of differentially 
methylated tiles. c, d, Distribution of methylation levels in LINE1 (c) and 
LTR (d) repeats. e, Expression of LINE1 in ductal cells, tested using two 
independent primer sets (n = 3). f, g, KL cells transduced with EV or LKB1 
assessed for methylation of LINE1 and 18S (f; n = 6, LINE1-1 and 18S; 
n = 4, LINE1-2), and LINE1 expression (g; n = 6). h, i, KL cells transduced 
with the indicated shRNAs were assessed for LINE1 and 18S methylation 
(h; n = 6) and LINE1 expression (i; n = 10). Data pooled from two (f, h) or 
representative of two (e, g, i) experiments. Error bars: s.d. * P < 0.05,  
* * P < 0.01, * * * P < 0.001.
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to the clinically approved DNMT inhibitor decitabine, as compared 
to K and KPC cell lines (IC50 KL: 2 nM; K: 138 nM; KPC: 258 nM) 
(Fig. 5d and Extended Data Fig. 9g–i). Similar results were obtained 
using additional DNMT inhibitors (RG108, EGCG and SGI1027; 
Extended Data Fig. 9j–m). Importantly, decitabine treatment caused 
striking regression of subcutaneous KL tumours, associated with 
necrosis, hyalinization, replacement of tumour glands with fibrosis, 
decreased tumour cell proliferation, and pronounced apoptosis 
(Fig. 5e–g). By contrast, KPC xenografts were unaffected by decitabine 
(Extended Data Fig. 9n–q). Thus, LKB1 deficiency confers specific 
hypersensitivity to inhibition of DNA methylation in vitro and in vivo.
Available human LKB1 mutant pancreatic cancer cell lines 
(COLO357 and SNU324) showed similar vulnerabilities. They exhib-
ited 70–90% inhibition of proliferation following PSAT1 knockdown, 
whereas a set of LKB1 wild-type pancreatic cancer lines showed 
modest responses (Extended Data Fig. 10a), consistent with prior 
results27 in LKB1 wild-type lines. PSAT1 inactivation also inhibited 
the growth of LKB1 mutant COLO357 xenografts but not LKB1 
wild-type MIAPACA2 xenografts (Extended Data Fig. 10b). Moreover, 
LKB1 restoration or PSAT1 silencing decreased global methylation in 
COLO357 cells but not in PANC1 or PATU-8988T cells (Extended Data 
Fig. 10c, d). LKB1 mutant lines also exhibited an increased response 
to decitabine in vitro and in vivo, and to the methionine salvage path-
way inhibitors 3DZA and cycloleucine (Fig. 5h, i and Extended Data 
Fig. 10e). Thus, both mouse and human LKB1 mutant pancreatic 
tumour cells are sensitized to inhibition of the serine pathway and to 
DNMT inhibition.
Discussion
In summary, we have defined a metabolic state central to tumorigenesis 
resulting from LKB1 loss in which glucose and glutamine-derived 
intermediates are channelled towards the SGOC network leading to 
increased DNA methylation (Extended Data Fig. 10f). Such interplay 
between metabolic control and epigenetic reprogramming has been 
proposed as a key mechanism for cancer development in the context 
of mutations in metabolic enzymes1,2,5. The present work provides 
evidence for a broader role of metabolic and epigenetic crosstalk in 
cancer pathogenesis, revealing that LKB1 mutant pancreatic cancer 
cells have a marked dependency on pathways linking glycolysis, serine 
metabolism and DNA methylation.
It appears probable that the influence of aberrant metabolism on epige-
netics contributes to cancer in the context of other oncogenic mutations. 
For instance, PI3K/AKT signalling controls acetyl- coenzyme A 
 metabolism to support histone acetylation and regulate growth- 
promoting genes28. Numerous oncogenic pathways rewire metabolism, 
and the circuits that are activated vary widely, with different genetic 
lesions favouring distinct fates of glucose, glutamine, fatty acids, and 
other nutrients. Thus, the resulting alterations in the levels of metabolites 
affecting chromatin regulation (for example, NAD+ /NADH, FAD, 
O-linked N-acetylglucosamine, free fatty acids, SAM and acetyl-CoA) 
may be fundamental to cancer-promotion. Varying conditions in the 
tumour microenvironment may alter tumour phenotypes via similar 
processes29,30.
The gain in DNA methylation at retrotransposons that we observed 
in KL cells is notable in light of the emerging view that these abundant 
repeat elements serve critical roles in host gene regulation25. Moreover, 
there is increasing evidence that reactivation of silenced retrotransposons 
may underlie the therapeutic benefit of DNMT inhibitors, serving to 
induce a type I interferon anti-viral defence program31,32. The basis for 
the widespread differences in response to DNMT inhibitors observed 
in vitro and in the clinic remains unclear. In this regard, our studies 
in KRAS mutant pancreatic ductal cells suggest that LKB1 status is a 
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Figure 5 | LKB1 deficiency confers hypersensitivity to DNA  
methylation inhibitors. a–c, Volume of subcutaneous tumours derived 
from KL cells transduced with Dox-inducible shRNAs (n = 6 tumours  
per condition). d, Decitabine IC50 for K, KL or KPC cells (n = 4).  
e–g, Decitabine treatment of KL xenografts (n = 20 tumours per condition).  
e, Tumour growth. f, Proportion of CK19+ tumour cells that are PCNA+ 
(n = 4 representative tumours), and ratio of cleaved-caspase 3 (CC3) to 
DAPI staining (n = 4 representative tumours). g, Haematoxylin and eosin 
staining of representative tumours (top; arrows: tumour glands, dotted 
line: hyalinization), and staining for the indicated markers (quantified in f).  
Insets: threefold magnification. h, Decitabine IC50 in human pancreatic 
cancer cell lines (red, LKB1 mutant; black, LKB1 wild type). i, Growth 
of COLO357 xenografts treated with decitabine (1 mg kg−1) or vehicle 
(n = 6 per group). Data pooled from three (h) or representative of two (d) 
experiments. Error bars: s.e.m. (a–c, i), s.d. (d–f). * P < 0.05, * * P < 0.01,  
* * * P < 0.001.
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genetic marker for DNMT inhibitor responsiveness. Because repeat 
element methylation does not strictly correlate with sensitivity to these 
treatments33, the precise mechanisms of the specific response of KL cells 
to DNMT inhibitors remain to be defined. In this setting, it will be of 
interest to determine the relative contributions of IFN pathway activa-
tion and of modulation of host gene expression. Together, our data point 
to novel therapeutic vulnerabilities in the context of LKB1 mutations, 
suggesting that it might be possible to use agents targeting nodes of this 
network in defined patient subsets, although additional studies will be 
needed to broadly establish these associations in human cancers.
Our findings and other recent reports highlight the importance 
in cancer of the deregulation of serine biosynthesis, which can result 
from amplification of genes encoding pathway enzymes23,34 or their 
transcriptional activation downstream of oncogenic drivers, including 
NRF235, c-MYC36–38, and mTOR39. Serine metabolism can fuel 
diverse biosynthetic pathways and contribute to energy production. 
Correspondingly, its functional role in aberrant growth appears context 
dependent, relating variously to supporting nucleotide biosynthesis, 
NADPH production, TCA cycle anaplerosis, and DNA or histone 
methylation. These findings underscore the emerging interest in devel-
oping new approaches to targeting components of the SGOC network 
as cancer therapeutics.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Extended Data Figure 1 | LKB1 suppresses KRASG12D-driven 
tumorigenesis and limits glycolysis in primary pancreatic ductal 
epithelial cells. a, Schematic of GEM models. Sox9-CreER, LKB1L/L,  
and LSL-KRASG12D/+ mice were crossed to generate four cohorts: WT  
(Sox9-CreER), L (Sox9-CreER;LKB1L/L), K (Sox9-CreER;LSL-KRASG12D/+) 
and KL (Sox9-CreER;LSL-KRASG12D/+;LKB1L/L). Genetic lesions were  
induced by intraperitoneal injections of tamoxifen at 6 weeks of age,  
after which mice were observed for signs of disease and killed when  
KL animals were moribund (20–25 weeks of age). The WT, K, and L  
mice had no signs of illness or other abnormalities at this time point.  
b, Haematoxylin and eosin-stained sections of representative pancreata 
from WT and L mice (n = 4 mice per group). Scale bars, 50 μ m.  
c, Schematic of primary pancreatic ductal epithelial cell system.  
Pancreatic ductal epithelial cells were isolated from LSL-KRASG12D/+  
and LSL-KRASG12D/+;LKB1L/L mice and infected with Adeno-Cre  
to generate K and KL cells. For studies comparing K, L, KL and WT  
genotypes, cells were isolated from FSF-KRASG12D/+;LKB1L/L mice and  
infected with Adeno-Flipase and/or Adeno-Cre, or neither. d, Volume  
and e, weight of subcutaneous tumours derived from ductal cells of the  
indicated genotypes (n = 4 tumours per group). Error bars show s.e.m.  
For source data on tumour volume, see Supplementary Data Table 4.  
f, Weight of subcutaneous tumours from K (n = 6), KL (n = 8) and KL  
cells transduced with retrovirus expressing LKB1 cDNA (rescue, n = 8).  
g, Number of colonies formed in soft agar by K (none detected) or KL  
cells (n = 6 independent biological replicates). Error bars show s.e.m.  
h, Proliferation of K and KL cells in nutrient-replete medium (n = 4).  
i, Proliferation of KL cells transduced with retroviruses expressing 
empty vector or LKB1 (rescue; n = 3). j, Proliferation of wild-type (WT), 
KRASG12D/+ (K), LKB1−/− (L) and KRASG12D/+;LKB1−/− (KL) cells 
(n = 6). k–t, In vitro studies of K and KL cells. k, Detection of GLUT1 
(SLC2A1) by immunofluorescence (scale bar, 20 μ m) or immunoblot. 
2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI) was used to 
visualize nuclei. Actin was used as the loading control. For gel source 
images see Supplementary Data Fig. 1. l, Steady-state ATP levels under 
nutrient-replete conditions measured by CellTiterGlo (Promega), 
normalized to cell number and expressed as relative to ATP levels in  
K cells (n = 4). m, Intracellular levels of pyruvate, lactate, and TCA cycle 
metabolites as detected by GC–MS. Values are normalized to cell number. 
Data are expressed as relative to the levels in K cells (n = 6 biological 
replicates). n, Three-day proliferation of cells in 25 mM glucose or acutely 
switched to media with the indicated reduced glucose concentrations 
(n = 6). Data are expressed as relative to day 0. o–q, Proliferation of cells 
treated with 5 mM 2-deoxyglucose (2DG) (o), 5 mM dichloroacetate 
(DCA) (p) or 20 μ M galloflavin (gallo) (q). Values are expressed as 
percentage of normal growth (2DG n = 6, DCA n = 8, gallo n = 6).  
r–t, WT, K, L and KL cells were measured for glucose uptake using 
2NBDG (r, n = 6), lactate release into the medium (s, n = 4), and expression 
of glycolytic genes (t, n = 6). Data are pooled from two (j, l, n–r) or three (t)  
experiments or representative of two (h, i, s) experiments. For all panels, 
error bars show s.d. unless otherwise stated; * P < 0.05, * * P < 0.01,  
* * * P < 0.001.
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Extended Data Figure 2 | LKB1 loss induces the serine–glycine–one-
carbon network. a, GSEA showing enrichment of proteins involved in 
the serine–glycine–one-carbon network18 in KL cells compared to K cells 
using global proteomics (n = 4 samples per group). b, Plot of isotopomer 
abundance of U[13C]glucose-derived intracellular M+ 3 lactate over time 
(n = 3 independent biological replicates). c, Plot of isotopomer abundance 
of U[13C]glucose-derived intracellular M+ 2 glycine over time (n = 3 
independent biological replicates). d, Intracellular levels of serine, glycine 
and glutamine as detected by GC–MS. Values normalized to cell number. 
Data are expressed as relative to the levels in K cells (n = 6 biological 
replicates). e, PSAT1 and GLDC expression determined by immunoblot 
in K and KL cells and in KL cells transduced with LKB1 cDNA. Actin was 
used as loading control. For gel source images see Supplementary Data 
Fig. 1. f, GSEA of RNA-seq data showing suppression of genes involved in 
glycolysis, serine biosynthesis, folate cycle and the serine–glycine–one-
carbon network upon re-expression of LKB1 cDNA in KL cells (rescue, 
n = 2 samples) compared to parental KL cells (n = 4 samples). g, Plot 
of isotopomer abundance of U[13C]glucose-derived intracellular M+ 3 
serine 6 h after addition of U[13C]glucose (n = 3 independent biological 
replicates). For all panels, error bars show s.d. unless otherwise stated;  
* P < 0.05, * * P < 0.01, * * * P < 0.001.
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 3 | See next page for caption.
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Extended Data Figure 3 | The de novo serine biosynthesis pathway is 
required for KL but not KPC tumour growth. a, Proliferation of KL 
cells transduced with vector or LKB1 cDNA and cultured in the presence 
or absence of 0.4 mM serine. Growth is expressed as relative to day 0 
(n = 3). LKB1 re-expression slows growth and results in sensitivity to 
serine deprivation. b, qRT–PCR showing effective knockdown of PSAT1 
in K, KL, KPC and KIC cells transduced with shControl or two different 
shRNAs against PSAT1 (n = 2). Data are expressed as relative to shControl 
for each cell line. 18S rRNA was used for normalization. c, Number of 
colonies formed in soft agar by KL cells transduced with shControl or two 
different shRNAs against PSAT1 (n = 6). d, Proliferation of K or KL cells 
transduced with shControl or two independent shRNAs against PSAT1 
in the absence of serine. Data are expressed as percentage of growth in 
the presence of 0.4 mM serine (n = 6). e, qRT–PCR showing effective 
knockdown of endogenous mouse PSAT1 (mPSAT1, endogenous) and 
forced expression of human PSAT1 (hPSAT1, exogenous) in KL cells 
transduced with shControl, shPSAT1-1, shPSAT1-2, vector or hPSAT1 
cDNA. Data are normalized to 18s rRNA (n = 2). f, Weight at the time 
of harvesting of subcutaneous tumours from KL cells transduced 
with shControl (n = 8), shPSAT1-1 (n = 12), or shSPAT1-2 (n = 12). 
Error bars show s.e.m. g, Haematoxylin and eosin-stained sections 
and immunofluorescence analysis of representative tumours derived 
from subcutaneous injections of KL cells transduced with shControl, 
shPSAT1-1, or shPSAT1-2. Note that PSAT1 knockdown tumours have 
a reduction in malignant glands (arrows) relative to the fibrotic stroma. 
Lower panels: anti-CK19 (green) was used to visualize the neoplastic 
epithelium and anti-PCNA (red) was used to mark proliferation. DAPI 
was used to stain nuclei (blue). h, Proliferation of KPC and KIC pancreatic 
cancer cells transduced with shControl or two independent shRNAs 
against PSAT1. Growth is expressed as relative to day 0 (n = 6 for KPC and 
n = 4 for KIC). i–k, KPC cells were transduced with shControl (n = 6), 
shPSAT1-1 (n = 6) or shSPAT1-2 (n = 4) and injected into SCID mice. 
i, Volume (left) and weight (right) of subcutaneous tumours. Error bars 
show s.e.m. For source data on tumour volume, see Supplementary Data 
Table 4. j, k, Tumours in i were stained using anti-CK19 antibody (green) 
to visualize the neoplastic epithelium and anti-PCNA staining (red)  
to mark proliferating cells. DAPI was used to stain nuclei (blue).  
The proportion of stained CK19+ cells is quantified in j (n = 4, 
representative tumours) and CK19+ cells with nuclear PCNA staining  
are quantified in j. There are no significant effects on any of these 
parameters. k, Haematoxylin and eosin-stained sections (top) and 
immunofluorescence analysis (bottom) of representative tumours. Scale 
bars, 100 μ m. Insets show threefold magnification. Data pooled from two 
(c, d) or representative of two (a, b, e) or three (h) experiments. For all 
panels, error bars show s.d. unless otherwise stated; * P < 0.05,  
* * P < 0.01, * * * P < 0.001.
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Extended Data Figure 4 | Characterization of serine–glycine–one-
carbon pathway in KL cells. a, Detailed graph of SGOC network. 
Enzymatic inhibitors used in this study are marked in red. b, ROS in K or 
KL cells transduced with shControl, shPSAT1-1 or shPSAT1-2 measured 
by DCFDA (left) and CellRox staining (right). Data are normalized to cell 
number (n = 4). c, Six-day proliferation assay of KL cells transduced with 
shControl, shPSAT1-1 or shPSAT1-2, showing lack of growth rescue by 
N-acetylcysteine (NAC). Data are expressed as relative to day 0 (n = 6).  
d, Three-day growth assay of KL cells transduced with shControl, 
shPSAT1-1 or shPSAT1-2, showing the lack of rescue by excess 
nucleosides (adenosine, guanosine, thymidine, uridine, cytidine; 1 mM 
each). Data are presented as percentage of the growth of shControl cells 
(n = 16). e, Proliferation of K or KL cells treated with aminooxyacetate 
(AOA). Data are expressed as relative to day 0 (n = 8). f, Five-day 
proliferation of K or KL cells treated with AOA and/or NAC. Data are 
expressed as relative to day 0 (n = 6). g, Data from RNA-seq (left) and 
quantitative proteomics (right) showing levels of genes involved in 
the production of SAM in K and KL. The data plotted are expressed as 
mean-centred values. h, Proliferation of K or KL cells treated with 2 mM 
cycloleucine. Data are expressed as percentage of the growth of vehicle 
treated cells (n = 12). Data are pooled from two (b–f, h) experiments.  
For all panels, error bars show s.d. unless otherwise stated; * P < 0.05,  
* * P < 0.01, * * * P < 0.001.
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ARTICLE RESEARCH
Extended Data Figure 5 | Deletion of LKB1 induces DNMT1 and 
DNMT3A expression and increases global DNA methylation. a, Heat 
map of RNA-seq data showing levels of the differentially regulated SAM-
using enzymes. Plotted data are expressed as mean centred values.  
b, Expression of DNMT1 and DNMT3A in K, KL, and KL cells transduced 
with LKB1 cDNA (rescue) was measured by qRT–PCR. Levels were 
normalized to 18S rRNA. Data are expressed as relative to K cells (n = 4, 
representative of two experiments). c, Immunoblots of lysates from K, 
KL or rescue cells were probed for DNMT1 or DNMT3A. Actin was 
used as loading control. For gel source images see Supplementary Data 
Fig. 1. d, Measurement of SAM in K and KL cells treated with 5-aza-2-
deoxycytidine (decitabine) or RG108 for 3 days. In each case, data are 
expressed as relative to the amount of SAM in vehicle-treated K cells, 
which was arbitrarily set to 1 (n = 6 independent replicates).  
e, Immunofluorescence staining and quantitation of 5mC in K or KL cells 
(77–130 cells). Scale bar, 25 μ m. f, Dot blot of DNA isolated from K or KL 
cells probed with anti-5mC antibody. Quantified signal was normalized 
to total DNA as measured by methylene blue staining (n = 4, independent 
replicates). g, Dot blot of DNA isolated from KL cells transduced with 
empty vector or LKB1 cDNA probed with anti-5mC antibody. Quantified 
signal was normalized to total DNA as measured by methylene blue 
staining (n = 3, independent replicates). h, Immunoblot analysis of  
histone 3 (H3) methyl marks from K or KL cells. Data are normalized 
to total H3 (K4me3, n = 2; K27me3, n = 5; K36me3, n = 5, independent 
replicates). For gel source images see Supplementary Data Fig. 1. i, Dot 
blot of DNA isolated from K or KL cells probed with anti-5hmC antibody. 
Quantified signal was normalized to total DNA as measured by methylene 
blue staining (n = 4, independent replicates). For all panels, error bars 
show s.d. unless otherwise stated; * P < 0.05, * * P < 0.01, * * * P < 0.001.
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Extended Data Figure 6 | Serine pathway activity sustains DNA 
methylation in KL cells. a, Dot blot of DNA isolated from K or KL cells 
transduced with shControl, shPSAT1-1 or shPSAT1-2 probed with anti-
5mC antibody. Total DNA was visualized by methylene blue staining. 
Graph shows quantified signal normalized to total DNA as measured 
by methylene blue staining (K cells, n = 4; KL cells, n = 8, independent 
replicates). b, Dot blot of DNA isolated from KPC cells transduced with 
shControl, shPSAT1-1 or shPSAT1-2 probed with anti-5mC antibody. 
The graph shows quantified signal normalized to total DNA (n = 4, 
independent replicates). c, Dot blot of DNA probed with anti-5mC 
antibody. DNA was isolated from KL cells first transduced with vector or 
human PSAT1 then transduced with shControl, shPSAT1-1 or shPSAT-2. 
Graph shows quantified signal normalized to total DNA as measured by 
methylene blue staining (n = 3, independent replicates). d, Expression  
of serine pathway genes and DNMT genes in WT, K, L or KL cells by  
qRT–PCR. Data are normalized to 18S and expressed as relative to K 
cells (n = 6, pooled data from two experiments). e, Plots of isotopomer 
abundance of U[13C]glucose-derived M+ 3 serine and M+ 2 glycine, 6 h 
after addition of U[13C]glucose (n = 6 independent biological replicates).  
f, Quantified DNA dot blot signal of DNA isolated from WT, K, L or 
KL cells probed with anti-5mC antibody normalized to total DNA as 
measured by methylene blue staining (n = 4, independent replicates).  
g, Five-day growth of WT, K, L or KL cells transduced with shControl or 
two shRNAs against PSAT1. Data are expressed as relative to day 0 (n = 4, 
pooled from two experiments). For all panels, error bars show s.d. unless 
otherwise stated; * P < 0.05, * * P < 0.01, * * * P < 0.001.
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Extended Data Figure 7 | See next page for cation.
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Extended Data Figure 7 | LKB1-mediated regulation of glycolysis–
SGOC–DNMT pathway involves the AMKP–mTOR axis. a–e, KL cells 
were transduced with vector, wild-type LKB1 or kinase-dead LKB1.  
a, Proliferation, expressed as relative to day 0 (n = 4). b, Glucose uptake 
measured using 2NBDG followed by fluorimetry (data normalized to cell 
number and expressed as relative to KL-vector cells (n = 8)). c, Lactate 
levels measured by fluorimetry 3 h after medium change, normalized to 
cell number (n = 8). d, Oxygen consumption rates measured in normal 
duct medium, followed by injections with 4 μ M oligomycin (O), 4 μ M 
FCCP (F), or 4 μ M antimycin A (A) (n = 3). e, Expression of the indicated 
genes measured by qRT–PCR (n = 4), with levels normalized to 18S  
rRNA. Data are expressed as relative to KL-empty vector (EV) cells.  
f, Immunoblot of K, KL or KL cells transduced with LKB1 cDNA (rescue). 
For gel source images see Supplementary Data Fig. 1. g, Immunoblot 
of K cells treated overnight with 10 μ Μ Compound C. For gel source 
images see Supplementary Data Fig. 1. h, i, Glucose uptake (h) and 3 h 
lactate production (i) in the same cells as in h. Data are normalized to cell 
number and expressed as relative to control K cells (glucose uptake, n = 3; 
lactate, n = 4). j, Glucose uptake in K or KL cells treated with vehicle or 
10 μ Μ Compound C. Data are normalized to cell number and expressed as 
relative to control K cells (n = 4). Note the blunted response of KL cells.  
k, qRT–PCR analysis of the indicated genes in the same cells as in h. Levels 
are normalized to 18S rRNA. Data are expressed as relative to control 
K cells (n = 6). l, Immunostaining for 5-mC (left) and quantification of 
staining (right) in K cells treated with vehicle or Compound C for 4 days 
(158–163 cells). m–q, K cells were transduced with shControl or shRNAs 
against AMPKa1 or AMPKa2. m, Glucose uptake. Data are normalized to 
cell number and expressed as relative to shControl-treated cells (n = 4). 
n, Steady-state ATP levels measured with CellTiterGlo (Promega), 
normalized to cell number and expressed as relative to ATP levels in 
shControl-treated cells (n = 4). o, Lactate levels measured by fluorimetry 
3 h after medium change. Data are normalized to cell number (n = 3).  
p, Immunostaining for 5-mC (left) and quantification of staining (right) 
(159–296 cells). q, Expression of the indicated genes determined by  
qRT–PCR. Levels are normalized to 18S rRNA. Data are expressed as 
relative to shControl cells (n = 4). r–u, KL cells were transduced with 
vector or an LKB1 cDNA and shControl or shRNAs against AMPKa1 
or AMPKa2. r, Glucose uptake. Data are normalized to cell number and 
expressed as relative to vector-shControl cells (n = 4). s, Steady-state ATP 
levels normalized to cell number and expressed as relative to ATP levels in 
EV-shControl cells (n = 4). t, Lactate levels 3 h after medium change. Data 
are normalized to cell number (n = 4). u, Proliferation expressed as relative 
to day 0 (n = 3). v, Impact of Torin 1 treatment on growth of K and KL cells 
(n = 4). w, Immunoblot of K and KL cells treated with vehicle or 25 nM 
Torin 1. For gel source images see Supplementary Data Fig. 1. x, Glucose 
uptake and 3 h lactate production in K or KL cells treated overnight with 
25 nM Torin 1. Data are normalized to cell number (n = 4). y, Isotopomer 
abundance of U[13C]glucose-derived serine and glycine in the same  
cells as in r (n = 3 independent replicates). Cells were labelled with  
U[13C]glucose for 6 h. z, Expression of the indicated genes in Torin-treated 
K (left) or KL cells (right) determined by qRT–PCR. Levels are normalized 
to 18S rRNA. Data are expressed as relative to control-treated cells (n = 4). 
Data are pooled from two (b, c, e, i–n, p–t, v, x, z) or representative of two 
(a, d, h, o) or three (u) experiments. Error bars show s.e.m. in d, s.d. in all 
other panels. * P < 0.05, * * P < 0.01, * * * P < 0.001.
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Extended Data Figure 8 | See next page for caption.
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
ARTICLERESEARCH
Extended Data Figure 8 | Loss of LKB1 increases DNA methylation 
in retrotransposon elements. a, Hierarchical clustering of K and KL 
samples based on methylation levels at 100-bp autosomal genomic tiles 
as measured by whole-genome bisulfite sequencing. b, Two-dimensional 
density plot for methylation at non-repetitive 100-bp autosomal genomic 
tiles in KL versus K cells. The yellow line shows the mean methylation of 
tiles. The dots represent differentially methylated tiles (FDR q-value  
< 0.05, methylation change > 0.1). There are 3,395 hypermethylated tiles 
and 1,270 hypomethylated tiles in KL cells versus K cells. c, Overlap of 
genes associated with differentially methylated regions and differentially 
regulated genes (hyper DMRs, hypermethylated regions; hypo DMRs, 
hypomethylated regions; DRGs, differentially regulated genes).  
d–j, Distribution of methylation density within the low-CpG-promoters 
(LCPs), high-CpG-promoters (HCPs), islands, shores, exons, introns and 
LTRs. Numbers reflect median values. k, Average percentile change in 
methylation in the same elements as in d–j as well as LINEs and LTRs. 
l, Number of genes containing retrotransposon repeat elements (sum 
of LINEs, SINEs, LTRs) among the set of differentially regulated genes 
(DRGs) in K versus KL cells and among all genes. Note that the DRGs are 
enriched for the presence of retrotransposons in their gene bodies (top), 
but not in their promoters (middle) or 3′ UTRs (bottom). m, Specific 
enrichment of LINE, SINE and LTR elements in the gene bodies of DRGs 
when compared to all genes in the genome.
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Extended Data Figure 9 | See next page for caption.
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Extended Data Figure 9 | LKB1 deficiency confers hypersensitivity to 
inhibitors of DNA methylation. a–c, Proliferation of K (a), KL (b) and 
KPC (c) cells transduced with shControl or two shRNAs against each of 
DNMT1 (D1) or DNMT3A (D3A). Data are expressed as relative to day 
0 (K and KL n = 6, KPC n = 4). d–f, Volume of subcutaneous tumours 
derived from KPC cells transduced with doxcycline (Dox)-inducible 
shRNAs against DNMT1 or DNMT3A (n = 4). Doxcycline was introduced 
to the drinking water when tumours reached 125 mm3. Error bars show 
s.e.m. For source data on tumour volume, see Supplementary Data Table 4. 
g, Apoptosis measured by caspase 3/7 activity in K or KL cells treated 
with decitabine for 48 h. Values are normalized to cell number (n = 3). 
h, i, Proliferation of KL cells transduced with empty vector (h) or LKB1 
cDNA (i) treated with decitabine. Data are expressed as relative to day 0 
(n = 3). j, Proliferation of KL cells transduced with empty vector or LKB1 
cDNA treated with RG108. Data are expressed as percentage of growth 
of untreated cells (n = 6). k–m, Proliferation of K or KL cells treated with 
RG108 (n = 6) (k), EGCG (n = 12) (l) or SGI1027 (n = 12) (m). Data are 
expressed as percentage of growth of untreated cells. n–q, Mice bearing 
subcutaneous KPC tumours were treated with decitabine (n = 12) or 
vehicle (n = 12) when tumours reached 125 mm3. n, o, Tumour volume (n) 
and final tumour weight (o). Error bars show s.e.m. For source data on 
tumour volume, see Supplementary Data Table 4. p, Haematoxylin and 
eosin-stained slides from representative tumours (top). Bottom, anti-CK19 
(green) was used to visualize the neoplastic epithelium and anti-PCNA 
(red) was used to mark proliferating cells. DAPI was used to stain nuclei 
(blue). q, Quantification of the CK19+ neoplastic epithelial compartment 
(%CK19+ cells/total cells; top). Quantification of CK19+ cells with nuclear 
PCNA staining (bottom; n = 6). Scale bars, 100 μ m. Insets are threefold 
magnification. Data pooled from two (a–c, j) or four (k–m) experiments 
or representative of two (h) or three (g) experiments. Error bars show s.d. 
unless otherwise stated; * P < 0.05, * * P < 0.01, * * * P < 0.001.
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Extended Data Figure 10 | See next page for caption.
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Extended Data Figure 10 | Vulnerabilities of human LKB1 mutant 
pancreatic cancer cell lines. a, Three-day growth of LKB1 wild-type 
(black) or LKB1 mutant (red) human pancreatic cancer cells. Data are 
expressed as relative to shControl-transduced cells, which is arbitrarily 
set to 100 (n = 3). b, Quantification of tumour volume of subcutaneous 
tumours derived from implantation of the indicated cells transduced with 
shControl or two shRNAs against PSAT1 (n = 4). Error bars show s.e.m. 
For source data on tumour volume, see Supplementary Data Table 4.  
c, Immunofluorescence staining and quantification of 5mC in COLO357, 
PANC1 and PATU-8988T cells transduced with shControl or two shRNAs 
against PSAT1 (607–760 cells for COLO357, 305–342 cells for PANC1 and 
623–889 cells for PATU-8988T). Scale bar, 25 μ m. Error bars show s.e.m. 
Data are expressed as fluorescence per nucleus. d, Detection of 5mC by 
immunofluorescence in COLO357 (LKB1-deficient) cells transduced with 
vector or wild-type LKB1. Quantification is presented as fluorescence 
per nucleus (438–618 cells). Scale bar, 25 μ m. Error bars show s.e.m. 
e, Three-day growth of LKB1 wild-type (black) or LKB1 mutant (red) 
human pancreatic cancer cells treated with 10 μ M 3-deazaadenosine 
(3DZA) (top) or 2 mM cycloleucine (CycloLeu) (bottom). f, Metabolic and 
epigenetic changes promoting transformation upon deletion of the tumour 
suppressor LKB1. Data pooled from (c, d) or representative of (a) two 
experiments. Error bars show s.d. unless otherwise stated; * P < 0.05,  
* * P < 0.01, * * * P < 0.001.
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